← All trials
NCT04382937
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 12, 2016
- Primary completion
- Apr 30, 2020
- Completion date
- Jul 31, 2020
- First posted
- May 11, 2020
- Last posted
- May 11, 2020
- Enrollment
- 215
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- PharmaEssentia Corp.Lead sponsor
- Clinipace LTDCollaborator
- PharmaEssentia Corp.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.